Is It Worth Adding Chemo to ICI for NSCLC in Older Adults?
No randomized trial has directly compared stand-alone ICI with chemoimmunotherapy in geriatric patients with NSCLC. Without strong data supporting the combined approach, oncologists may stay away from offering chemoimmunotherapy to older patients, especially to those with multiple comorbidities, given concerns about increased toxicity.
To address the evidence gap, investigators linked Medicare and Surveillance, Epidemiology, and End Results data to compare outcomes between 14,249 older patients with NSCLC who received ICI alone (pembrolizumab or nivolumab) and 3432 treated with ICI and platinum doublet chemotherapy. Patients were aged 74 years, on average, and at least 66 years. The median follow-up duration was 211 days.
The team weighed the risks and benefits of chemoimmunotherapy vs stand-alone ICI to answer a key question: Is adding chemotherapy to ICI worth it for elderly patients with NSCLC?
The findings were recently published in Jama Oncology .
Benefits: Prolonged Survival in First Line
In the upfront setting, chemotherapy add-on reduced patients' mortality risk by 34% compared with ICI alone. Benefits were slightly more notable in women (hazard ratio [HR], 0.62) than in men (HR, 0.72).
Patients with autoimmune disease — who are often excluded from trials and who made up almost 20% of the study population — benefited the most, with a mortality risk reduction of 49%.
A similar mortality benefit was observed in patients aged 66-75 years and those aged 76 years or older, 'which is notable given that immune senescence is hypothesized to lessen ICI treatment response in patients older than 75 years,' wrote the investigators, led by James Heyward, PhD, a pharmacoepidemiologist at Johns Hopkins Bloomberg School of Public Health in Baltimore.
However, in the second or later lines of treatment, patients did not experience a significant survival benefit with chemoimmunotherapy (HR, 0.94; 95% CI, 0.68-1.03).
Risks: Increased Toxicity
Adding chemotherapy in the first-line setting increased the risk for severe immune-related adverse events (AEs), which can include pneumonitis, colitis, hepatitis, and myocarditis, by 18%. Severe AEs were more common in men (HR, 1.29) than in women (HR, 1.08).
Patients aged 76 years or older had the highest risk (30%) for severe immune-related AEs.
However, older patients did not have an increased risk for severe immune-related AEs in second and later lines.
The study did not consider chemotherapy toxicities.
Is It Worth It?
The team extrapolated from their data to calculate the harm-benefit trade-off of adding ICI to chemotherapy in older patients.
The researchers found that for each extra year of life gained with first-line chemoimmunotherapy, the risk for severe immune-related AEs would be 0.31. Put differently, 31% of patients predicted to gain 1 extra year of life were likely to experience one severe immune-related AE.
Past studies have found that patients are often willing to accept one severe AE for 1 year of added survival, which indicates that chemoimmunotherapy in the first line may be worth it for older patients with NSCLC.
'Given patient prioritization of survival benefits vs prevention of adverse effects, patients may prefer to initiate treatment with ICI + chemotherapy, albeit with careful follow-up for mitigation of severe immune-related AEs,' the investigators wrote.
But, the authors noted, 'men experienced more harm and less benefit than women' in the first-line setting, which is consistent with previous research.
And patients with an autoimmune disorder who received chemoimmunotherapy had a slightly higher risk for severe immune-related AEs (HR, 1.22) than those without a disorder (HR, 1.16).
Still, the authors said, 'the reduction in mortality was also the highest for this group of patients, suggesting that the potential benefits of treatment may outweigh the potential harms.'
In the second and later lines, the researchers found no increased risk for immune-related AEs with chemoimmunotherapy. Given the lack of statistically significant mortality benefit, the results suggest that stand-alone ICI are a better approach in this setting.
Overall, this study provides 'a valuable contribution to an ongoing and complex discussion,' said medical oncologist Alessio Cortellini, MD, PhD, an immunotherapy and lung cancer specialist at Imperial College London, London, England, who was not involved in the research.
However, it will be important to closely monitor patients for severe immune-related AEs.
'While adding chemotherapy to immunotherapy may be appropriate for selected older adults with NSCLC, I remain cautious about its widespread use in frail patients,' Cortellini added. 'Until we have dedicated trials in frail populations, the decision to use [chemotherapy-ICI]combinations in older adults should be highly individualized.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
4 minutes ago
- Medscape
Hep B Transmitted by Shared Glucometers in Care Facility
Hepatitis B virus (HBV) was transmitted to a person in a long-term care facility via shared blood glucose monitors, the US Centers for Disease Control and Prevention (CDC) reported. 'Sharing glucometers presents a risk for HBV transmission that can be reduced by routine HBV vaccination of persons with diabetes and dedicating individual glucometers to a single resident,' the CDC said in the August 7 issue of the Morbidity and Mortality Weekly Report. During 2008-2019, the CDC reported 15 outbreaks of HBV and hepatitis C virus in US long-term care facilities due to the same practice. In the recent case, the patient was 69 years old with diabetes and no history of HBV or HBV vaccination when diagnosed with acute HBV in May 2024. Investigation revealed that the patient lived in a skilled nursing facility room close to another resident with diabetes who had a previously unreported chronic HBV infection. During March-April 2024, both received glucose monitoring from one of two devices stored on a single medical cart, and the recorded timing between tests suggested that disinfecting practices had not been followed. However, the CDC pointed out that even when disinfection protocols are followed, HBV transmission can still occur with sharing of equipment that is in contact with blood. For that reason, the agency recommends assigning each resident a dedicated glucometer and administering HBV vaccination to all people aged 60 years and older with diabetes. 'The findings of this investigation highlight [assisted monitoring of blood glucose] as a risk factor for HBV transmission and provide evidence that skilled nursing facilities might be an appropriate setting to offer hepatitis B vaccination,' the CDC concluded. Miriam E. Tucker is a freelance journalist based in the Washington DC area. She is a regular contributor to Medscape Medical News, with other work appearing in the Washington Post, NPR's Shots blog, and Diatribe. She is on X @MiriamETucker and BlueSky @
Medscape
4 minutes ago
- Medscape
Lithium Deficiency May Spur Alzheimer's, Guide Treatment
Lithium, long prescribed for bipolar disorder and as an adjunct in depression, is essential for brain resilience, and new research suggests that deficiency of the mineral in neural tissue may contribute to Alzheimer's disease (AD). For the first time, investigators found that lithium is sequestered by amyloid plaques in AD, depleting its availability in neural tissue. In addition, they found that a novel lithium-based compound engineered to bypass plaque binding reversed synaptic and cognitive deficits in mouse models and has the potential to restore memory In addition, analyses of human brain tissue showed that loss of lithium was one of the earliest changes leading up to AD. In mice with lowered lithium levels, researchers found similar accelerated brain pathology and memory decline. Amyloid-beta (Aβ) plaques in the brain are a hallmark of AD. When they develop early in the disease, they bind to lithium, inhibiting uptake of the mineral in the brain and lead to the reduced lithium levels observed in the study. Researchers also identified a plaque-evading lithium salt that, when administered to mouse models with AD, was associated with significantly reduced AD-type pathology and improved memory. 'We found that endogenous lithium in the brain changed during aging, and this could be recapitulated in mouse models of the disease,' coinvestigator Bruce A. Yankner, MD, Department of Genetics, Harvard Medical School, Boston, told Medscape Medical News. 'Importantly, by simply depleting [lithium] from the mouse diet, we found that it had protean effects, changing the cell biology of the aging brain, the pathology of Alzheimer's disease, and parameters of neurocognitive function,' Yankner added. The findings were published online on August 6 in Nature . A 10-Year Journey About 10 years ago, the same researchers found that the neuron-restrictive silencer factor, the transcription factor (REST), which was previously established as a central regulator of neural development, was involved in the brain's response to aging and AD, Yankner said. A component of this discovery was the regulation of REST by the Wnt signaling pathway. Lithium is a classic approach to activating Wnt signaling, he added. 'While using lithium in this context, we were impressed with its ability to reduce all the various neuropathologic and cellular changes in animal models of Alzheimer's,' Yankner said. 'I wondered whether lithium itself might be part of the disease mechanism.' So the Yankner and his team set out to determine whether there might be endogenous lithium in the human brain. Using high-sensitivity inductively coupled plasma mass spectrometry adapted for human brain and blood samples, researchers measured 27 abundant and trace metals in the brains and blood of individuals with normal cognition, amnestic mild cognitive impairment (MCI), or AD. To Yankner's surprise, of all the major and trace metals analyzed, only lithium was significantly reduced in the prefrontal cortex of participants with MCI or AD. It also had the lowest P value of any metal. 'Other metals changed in AD, but they did not show significant changes in MCI, the earliest stage of memory loss,' Yankner said. In addition, every case of MCI and AD showed significant concentrations of lithium in Aβ plaques. 'Together, these results indicate that endogenous [lithium] homeostasis is perturbed in the brain in MCI and AD,' the investigators wrote. Lithium as a Potential Treatment? The researchers also found cortical distribution of endogenous lithium in Aβ precursor proteins in mice. Reducing cortical lithium by 50% not only increased Aβ and phosphor-tau in the animal models but also increased inflammatory microglial activation and cognitive decline. The use of lithium orotate, a lithium salt with reduced amyloid binding, led to reduced pathological changes, reduced memory loss, and restored microglial function, and may be 'a potential approach to the prevention and treatment of AD,' the researchers wrote. Lithium toxicity is a concern for older patients who receive highly concentrated formulations of the drug to treat psychiatric illness. But lithium orotate is significantly less concentrated and mice treated with the compound showed no evidence of toxicity. Yankner said that, from a clinical standpoint, his team will now advance on two fronts. First, they are exploring ways to detect lithium deficiency early, either by measuring it directly or through surrogate markers. Second, they aim to identify subpopulations most likely to benefit from lithium based on clinical and biochemical criteria. 'As a neuroscientist, I am excited about exploring the physiology of lithium in the brain. Our single nucleus RNA sequencing data suggests that there are significant effects of endogenous lithium on all brain cell types we examined,' Yankner said. 'I believe that future studies may uncover some very interesting biology,' he added. Several Limitations Commenting on the study for Medscape Medical News, Ozama Ismail, PhD, director of Scientific Programs at the Alzheimer's Association, said a major limitation to interpreting the findings is the use of a mouse model. 'Animal models do not directly replicate Alzheimer's in humans; rather, they can provide some insights into the biology of disease progression and development. The mouse models have been modified to accumulate amyloid beta, a hallmark protein that builds up in the brains of people with Alzheimer's,' said Ismail, who was not involved with the research. He noted that studies in mouse models represent a crucial early step in the development of any therapeutic intervention. 'However, before we can know the exact role of this metal in Alzheimer's biology, much more research is needed to understand the effect of lithium levels in the brain in people from a wide variety of communities and different health status,' he said, adding that large clinical trials are also needed to understand whether lithium really can be therapeutic for AD. Ismail emphasized the importance of investigating all potential therapies, noting that, as with other major diseases, effective treatment for AD will likely require a combination of medications and lifestyle interventions. Regarding the human analyses in the current study, he emphasized that the findings do not clarify the mechanism behind the reduced lithium levels — whether the disease itself causes the decrease or another factor indirectly lowers them. As for the human analyses in the current study, he pointed out that the findings do not explain the mechanism driving the reduced lithium in these individuals — whether the disease itself is causing the reduction or if another factor may be indirectly lowering the levels. 'This is where the animal study comes in, as it tries to get to the mechanism, and suggests that when lithium is lower, amyloid is higher. This might be due to immune changes or metabolic changes, and we need more research to understand this better,' Ismail said.
Medscape
34 minutes ago
- Medscape
FDA Warns About ‘Mousse' Sunscreens
The FDA has issued warnings to several manufacturers of 'mousse' or 'whipped cream' sunscreen products, according to the agency's website. Over-the-counter sunscreen products are regulated as drugs under the Federal Food, Drug, and Cosmetic Act because they are intended to prevent sunburn and reduce the risk for skin cancer and premature skin aging. However, the currently approved formulations include oils, creams, lotions, sticks, gels, powders, ointments, pastes, and sprays but not foam, mousse, or whipped formulas. Therefore, these formulations need to go through the new drug application process to earn FDA approval. As of August 18, warnings have been sent to five companies: Supergoop!, Vacation Inc., Kalani Sunwear, K & Care Organics, and Fallien Cosmeceuticals (manufacturer of TiZo sunscreen), according to the FDA. For example, the warning letter to Vacation Inc. states that the company's product is misbranded and therefore misleading to consumers. 'To date, no final order has been issued by the Secretary under 505G(b) or 505G(c) that would authorize marketing of a sunscreen in foam (aka, mousse or whip) dosage form,' the letter states. In addition, Vacation, in particular, markets sunscreen products similar in appearance to whipped cream products, both in the packaging and dispenser style. The website's description of the bottle's actuator producing 'perfect, star-shaped mountains of foam, inspired by everyone's favorite after dinner indulgence' has prompted concerns about ingestion by children who mistake it for actual whipped cream. Efficacy Unconfirmed Sunscreens are considered over-the-counter drugs, so they are held to a different standard compared with other skincare products, Adam Friedman, MD, professor and chair of dermatology at George Washington University School of Medicine and Health Sciences, Washington, DC, said in an interview. The companies selling mousse sunscreen products have not gone through the proper testing, 'so we don't know whether the SPF [sun protection factor] advertised is actually true,' Friedman said. Even if the companies had tested the products, mousses are not currently within the FDA's sunscreen monograph and would have to be added, although that may happen in the future if companies research the effectiveness of the products correctly, he noted. Part of the testing process is to determine how the vehicle interfaces with the skin and affects the product's ability to protect skin from sun damage, Friedman explained. Ultimately, the best sunscreen is the one someone will use consistently, he pointed out. But there is no quality assurance with any of the mousse sunscreens and the companies' responses to the FDA warnings remain to be seen. The popularity of the mousse and whipped sunscreen products may promote appropriate testing, and arguably, using a mousse sunscreen could be an improvement over using no sunscreen at all, Friedman told Medscape Medical News . However, he advises clinicians to stop short of actively endorsing these products if patients ask about them. 'Be honest with patients,' he said. 'We don't know whether these products are safe and effective because the manufacturers didn't follow the rules before marketing them.'
